StarD13在上皮性卵巢癌组织中的表达及其与预后的关系

目的:检测上皮性卵巢癌患者癌组织中类固醇敏感性调节蛋白相关脂类转运体结构域13（StarD13）的表达水平，并探讨其表达水平与患者预后的相关性。方法:选取2013年1月至2015年4月于本院接受治疗并在术后经病理证实的84例上皮性卵巢癌患者（上皮性卵巢癌组）作为研究对象；同期选取卵巢良性肿瘤患者96例（卵巢良性肿瘤组）。采用免疫组织化学法检测组织中StarD13的表达水平；通过Ualcan数据库检索，比较正常卵巢组织与卵巢癌组织中StarD13的表达水平；分析癌组织中StarD13的表达与上皮性卵巢癌患者临床病理特征的关系；分析癌组织中StarD13的表达与上皮性卵巢癌患者生存率的关系；COX单因素和多因素分析上皮性卵巢癌患者预后不良的危险因素。结果:Ualcan数据库中，卵巢癌组织中StarD13蛋白表达水平低于正常卵巢组织（P＜0.05）；本研究结果与Ualcan数据库一致，上皮性卵巢癌组织中StarD13蛋白阳性表达率低于卵巢良性肿瘤（P＜0.05）；上皮性卵巢癌患者癌组织中StarD13的表达与年龄、肿瘤最大径、肿瘤组织分型无关（P＞0.05），与FIGO临床分期、肿瘤分化程度、淋巴结转移情况有关（P＜0.05）；StarD13阴性表达患者5年内存活率（28.85%）低于StarD13阳性表达患者（75.00%）（P＜0.05）；肿瘤低分化是上皮性卵巢癌患者预后不良的独立危险因素（P＜0.05），StarD13阳性表达是上皮性卵巢癌患者预后不良的保护因素（P＜0.05）。结论:上皮性卵巢癌组织中StarD13大部分呈阴性表达，与患者临床病理特征及预后密切相关。

Expression of StarD13 in epithelial ovarian cancer tissues and its relationship with prognosis

Objective:To detect the expression level of St AR-related lipid transfer domain protein 13 (StarD13) in epithelial ovarian cancer tissues,and to explore its correlation with prognosis.Methods:From January 2013 to April 2015,84 patients with epithelial ovarian cancer (epithelial ovarian cancer group) who were treated in our hospital and confirmed by pathology after operation were selected as the research objects.At the same time,96 patients with benign ovarian tumor (benign ovarian tumor group) were selected.The level of StarD13 was detected by immunohistochemistry.According to the Ualcan database,the expression level of StarD13 in normal ovarian tissues and ovarian cancer tissues was compared.The relationship between StarD13 expression and clinicopathological parameters of epithelial ovarian cancer was analyzed.The relationship between the expression of StarD13 and the survival rate of patients with epithelial ovarian cancer was analyzed.COX univariate and multivariate analysis were used to analyze the risk factors for poor prognosis of epithelial ovarian cancer patients.Results:In the Ualcan database,the expression level of StarD13 protein in ovarian cancer tissues was lower than that in normal ovarian tissues (P＜0.05).The results of this study was consistent with those of Ualcan database.The positive expression rate of StarD13 protein in epithelial ovarian cancer group was lower than that in benign ovarian tumor group (P＜0.05).The expression of StarD13 in epithelial ovarian cancer tissues was not correlated with age,tumor size and tumor tissue type (P＞0.05),but correlated with FIGO clinical stage,tumor differentiation and lymph node metastasis (P＜0.05).The 5-year survival rate of patients with StarD13 negative expression (28.85%) was lower than that of patients with StarD13 positive expression (75.00%) (P＜0.05).In addition,poor differentiation was an independent risk factor for poor prognosis in patients with epithelial ovarian cancer (P＜0.05),and positive expression of StarD13 was a protective factor for poor prognosis in patients with epithelial ovarian cancer (P＜0.05).Conclusion:StarD13 is mostly negative in epithelial ovarian cancer tissues,which is closely related to clinicopathological parameters and prognosis.